18
Aug 2026
Nanoplatelets, a potential drug delivery vehicle for targeted cancer therapy
Short-lived radioactive isotopes, or radioisotopes, can image tumors or inflict high levels of cellular damage to them.
-
Life can be betterWe are developing drug products isolated from plant extracts
with history in traditional medicine. -
Improving healthImproving health and wellbeing of the people
is our ultimate goal at Mercury Pharmaceuticals. -
ENTREPRENEURIAL MINDSETHands-on approach to manage projects with proactivity and flexibility.
Welcome to Mercury Pharmaceuticals
We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
OUR Science
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
- NeuroscienceAmong the global leaders in Neuroscience
- OncologyTreatments for niche cancers.
- Research & Development Building a sustainable R&D pipeline.
- Clinical trialsTesting new treatments and ensure their efficacy and safety by conducting clinical trials.
MERCURY trials
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Cancer
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Neuroscience
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
STAY INFORMED!
18
Aug 2026
What a 38-year study suggests about red meat, white meat, and mortality
Lower intake of red and processed meat was associated with small reductions in all-cause, heart disease, cancer, and stroke mortality in a cohort of nearly one million US adults followed for decades. White-meat-only diets showed additional benefits in some subgroups, while vegetarian diets produced few consistent associations and were limited by small participant numbers and a single baseline dietary assessment.
18
Aug 2026
Whole grains, legumes and vegetables stand out in a major review of diabetes diets
Healthy plant-based diets rich in whole grains, legumes, fruits, vegetables, nuts, and seeds are associated with better glycemic control and a lower risk of type 2 diabetes. The review finds that food quality and processing matter more than simply avoiding animal foods, while unhealthy plant-based patterns and higher red and processed meat intake are associated with greater metabolic risk.
18
Aug 2026
A New York skincare survey found mercury where consumers might not expect it
Targeted surveillance of 197 skin-lightening and skincare products purchased in New York City from 2009 to 2022 found detectable mercury in 29%, with 18% exceeding the FDA’s 1 ppm limit and concentrations reaching 27,000 ppm. All mercury-positive products were manufactured abroad, mercury was rarely disclosed on labels, and the findings highlight regulatory, health-equity, and environmental justice concerns.
Why Us?
Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.